Breast Cancer Coverage from Every Angle

Initial Therapy With Abemaciclib for Advanced Breast Cancer

By: Joan Eve Malcoun Swain, MMSc, PA-C
Posted: Monday, December 4, 2017

Abemaciclib, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor, in combination with a nonsteroidal aromatase inhibitor was shown to be effective in hormone receptor–positive, HER2-negative advanced breast cancer. The results of the MONARCH 3 study were published by Matthew Goetz, MD, of the Mayo Clinic in Rochester, Minnesota, and colleagues in the Journal of Clinical Oncology.

The double-blind, randomized phase III study included 493 postmenopausal women. Patients with hormone receptor–positive, HER-2 negative breast cancer who did not respond to previous endocrine therapy met the inclusion criteria. Those assigned to the treatment group received abemaciclib at 150 mg twice a day in combination with a daily dosed nonsteroidal aromatase inhibitor (anastrozole at 1.0 mg or letrozole at 2.5 mg) versus the nontreatment placebo group.

An investigator-assessed interim analysis was conducted after 194 progression-free survival events occurred. The median progression-free survival rate was significantly increased in the treatment group, with a hazard ratio of 0.54. The response rate was 59% in the treated group compared with 44% in the placebo group. The most frequent adverse events observed with abemaciclib were neutropenia, diarrhea, and leukopenia.  

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.